Multiple antigen presenting system (MAPS): state of the art and potential applications
ABSTRACTIntroduction Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2023.2299384 |
| _version_ | 1797362162969083904 |
|---|---|
| author | Richard Malley Ying-Jie Lu Shite Sebastian Fan Zhang David O. Willer |
| author_facet | Richard Malley Ying-Jie Lu Shite Sebastian Fan Zhang David O. Willer |
| author_sort | Richard Malley |
| collection | DOAJ |
| description | ABSTRACTIntroduction Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.Areas covered This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.Expert opinion The utilization of high-affinity non-covalent biotin–rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance. |
| first_indexed | 2024-03-08T16:03:31Z |
| format | Article |
| id | doaj.art-6933908c16ac4ca2bebe159186989176 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-08T16:03:31Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-6933908c16ac4ca2bebe1591869891762024-01-08T09:49:34ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123119620410.1080/14760584.2023.2299384Multiple antigen presenting system (MAPS): state of the art and potential applicationsRichard Malley0Ying-Jie Lu1Shite Sebastian2Fan Zhang3David O. Willer4Division of Infectious Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, USADivision of Infectious Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, USAGSK, Research and Development, Cambridge, MA, USADivision of Infectious Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, USAGSK, Global Medical Affairs, Vaccines Research and Development, Mississauga, Ontario, CanadaABSTRACTIntroduction Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.Areas covered This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.Expert opinion The utilization of high-affinity non-covalent biotin–rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.https://www.tandfonline.com/doi/10.1080/14760584.2023.2299384Bacterial vaccinesbiotin–rhizavidin interactioncell-mediated immunityglycocomplexMAPSmultiple antigen presenting system |
| spellingShingle | Richard Malley Ying-Jie Lu Shite Sebastian Fan Zhang David O. Willer Multiple antigen presenting system (MAPS): state of the art and potential applications Expert Review of Vaccines Bacterial vaccines biotin–rhizavidin interaction cell-mediated immunity glycocomplex MAPS multiple antigen presenting system |
| title | Multiple antigen presenting system (MAPS): state of the art and potential applications |
| title_full | Multiple antigen presenting system (MAPS): state of the art and potential applications |
| title_fullStr | Multiple antigen presenting system (MAPS): state of the art and potential applications |
| title_full_unstemmed | Multiple antigen presenting system (MAPS): state of the art and potential applications |
| title_short | Multiple antigen presenting system (MAPS): state of the art and potential applications |
| title_sort | multiple antigen presenting system maps state of the art and potential applications |
| topic | Bacterial vaccines biotin–rhizavidin interaction cell-mediated immunity glycocomplex MAPS multiple antigen presenting system |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2023.2299384 |
| work_keys_str_mv | AT richardmalley multipleantigenpresentingsystemmapsstateoftheartandpotentialapplications AT yingjielu multipleantigenpresentingsystemmapsstateoftheartandpotentialapplications AT shitesebastian multipleantigenpresentingsystemmapsstateoftheartandpotentialapplications AT fanzhang multipleantigenpresentingsystemmapsstateoftheartandpotentialapplications AT davidowiller multipleantigenpresentingsystemmapsstateoftheartandpotentialapplications |